LAM focuses on Chinese diabetic ulcer market:
This article was originally published in Clinica
Executive Summary
LAM Pharmaceutical is to explore distribution and strategic alliance opportunities in China with Benchmark Global Capital Group's Chinese subsidiary, one of the leading US-based investment and consulting firms in China. Lewiston, New York-based LAM develops the IPM wound gel, for the management of certain skin ulcers and wounds. Benchmark notes that, although China has the world's largest diabetic population, with almost 65 million patients, there are currently no effective products for treating diabetic wounds and ulcers on the Chinese market.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.